Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from Mass General Brigham, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in JAMA Internal Medicine.

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones. In a study led by investigators from Mass General Brigham, researchers found that there was an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of developing kidney stones. Their findings are reported in JAMA Internal Medicine.

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital, founding members of the Mass General Brigham healthcare system, worked together to conduct the analysis. The study included data from three nationwide databases of patients with type 2 diabetes who were seen in routine clinical practice. The team analyzed information from 716,406 adults with type 2 diabetes who had started taking an SGLT2 inhibitor or two other classes of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors. Patients who began taking SGLT2 inhibitors had a 30 percent lower risk of developing kidney stones than those taking GLP1 agonists and about a 25 percent lower risk than those taking DPP4 inhibitors. The findings were consistent across sex, race/ethnicity, history of chronic kidney disease and obesity.

“Our findings could help inform clinical decision making for patients with diabetes who are at risk for developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medicine at Brigham and Women’s Hospital.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 2 multiplied by 3?

Explore More

Scientists find that supplementation with a special omega-3 lipid could treat acute kidney injury

Researchers from Singapore have identified a potential dietary supplement that may improve recovery following acute kidney injury (AKI). The finding, published in the Journal of Lipid Research, comes from a

Why are male kidneys more vulnerable to disease than female kidneys? Mouse study points to testosterone

Female kidneys are known to be more resilient to disease and injury, but males need not despair. A new USC Stem Cell-led study published in Developmental Cell describes not only

New mathematical model shows how the body regulates potassium

Having levels of potassium that are too high or too low can be fatal. A new mathematical model sheds light on the often mysterious ways the body regulates this important